Olli Lohi, Professor of Pediatric Hematology and Oncology at Tampere University, shared on X:
“Phase I/II SAVE trial: an all-oral combination of revumenib + decitabine/cedazuridine + venetoclax in 42 patients with relapsed/refractory AML achieved an 88% overall response rate and 71% CRc. Patients included KMT2A-rearranged (40%), NPM1-mutant (38%), and NUP98-rearranged (21%) AML. MRD negativity was achieved in 80% of patients reaching CR/CRh. Super-promising combo․”
Title: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Authors: Ghayas C. Issa, Branko Cuglievan, Georgina El Hajjar, Wei Ying Jen, Alex Bataller, Nicholas J. Short, Courtney D. DiNardo, Yesid Alvarado, Sanam Loghavi, Dzifa Yawa Duose, Baili Zhang, Ken Furudate, Jing Ning, Lianchun Xiao, Elie Mouhayar, Alessandro Pinto, Aram Bidikian, Erika Thompson, Naval Daver, Guillermo Garcia-Manero, Aziz Farhat, David McCall, Tapan M. Kadia, Hussein A. Abbas, Sheila Tan, Alexandre Bazinet, Elias Jabbour, Guillermo Montalban-Bravo, Farhad Ravandi, Koichi Takahashi, Michael Andreeff, Hagop M. Kantarjian
Read the full article.
You can also read:
Myeloma Paper of the Day, August 4th, Suggested by Robert Orlowski